[go: up one dir, main page]

Growth hormone-releasing peptide 6 (GHRP-6) (developmental code name SKF-110679), also known as growth hormone-releasing hexapeptide, is one of several synthetic met-enkephalin analogues that include unnatural D-amino acids, were developed for their growth hormone-releasing activity and are called growth hormone secretagogues. They lack opioid activity but are potent stimulators of growth hormone (GH) release. These secretagogues are distinct from growth hormone releasing hormone (GHRH) in that they share no sequence relation and derive their function through activation of a completely different receptor. This receptor was originally called the growth hormone secretagogue receptor (GHSR), but due to subsequent discoveries, the hormone ghrelin is now considered the receptor's natural endogenous ligand, and it has been renamed as the ghrelin receptor. Therefore, these GHSR agonists act as synthetic ghrelin mimetics.

GHRP-6
Clinical data
ATC code
  • None
Pharmacokinetic data
BioavailabilityOral: <1.0%[1]
Elimination half-life2.5 hours[2]
Identifiers
  • L-histidyl-D-tryptophyl-L-alanyl-L-tryptophyl-D-phenylalanyl-L-Lysinamide
CAS Number
PubChem CID
ChemSpider
UNII
CompTox Dashboard (EPA)
Chemical and physical data
FormulaC46H56N12O6
Molar mass873.032 g·mol−1
3D model (JSmol)
  • C[C@@H](C(=O)N[C@@H](Cc1c[nH]c2c1cccc2)C(=O)N[C@H](Cc3ccccc3)C(=O)N[C@@H](CCCCN)C(=O)N)NC(=O)[C@@H](Cc4c[nH]c5c4cccc5)NC(=O)[C@H](Cc6c[nH]cn6)N
  • InChI=InChI=1S/C46H56N12O6/c1-27(54-44(62)39(20-29-23-51-35-15-7-5-13-32(29)35)57-43(61)34(48)22-31-25-50-26-53-31)42(60)56-40(21-30-24-52-36-16-8-6-14-33(30)36)46(64)58-38(19-28-11-3-2-4-12-28)45(63)55-37(41(49)59)17-9-10-18-47/h2-8,11-16,23-27,34,37-40,51-52H,9-10,17-22,47-48H2,1H3,(H2,49,59)(H,50,53)(H,54,62)(H,55,63)(H,56,60)(H,57,61)(H,58,64)/t27-,34-,37-,38+,39+,40-/m0/s1 ☒N
  • Key:WZHKXNSOCOQYQX-FUAFALNISA-N ☒N
 ☒NcheckY (what is this?)  (verify)

It has been discovered that when GHRP-6 and insulin are administered simultaneously, GH response to GHRP-6 is increased (1). However, the consumption of carbohydrates and/or dietary fats, around the administration window of GH secretagogues significantly blunts the GH release. A recent study in normal mice showed significant differences in body composition, muscle growth, glucose metabolism, memory and cardiac function in the mice being administered the GHRP-6 (2). There are still many questions regarding this fairly new compound.

See also

edit

References

edit
  1. ^ Hartman ML, Farello G, Pezzoli SS, Thorner MO (1992). "Oral administration of growth hormone (GH)-releasing peptide stimulates GH secretion in normal men". J Clin Endocrinol Metab. 74 (6): 1378–84. doi:10.1210/jcem.74.6.1592884. PMID 1592884.{{cite journal}}: CS1 maint: multiple names: authors list (link)
  2. ^ Cabrales A, Gil J, Fernández E, Valenzuela C, Hernández F, García I, et al. (January 2013). "Pharmacokinetic study of Growth Hormone-Releasing Peptide 6 (GHRP-6) in nine male healthy volunteers". European Journal of Pharmaceutical Sciences. 48 (1–2): 40–46. doi:10.1016/j.ejps.2012.10.006. PMID 23099431.

Further reading

edit